Premium
Steady‐state moxalactam kinetics: Comparisons with other cephalosporins
Author(s) -
Garzone Pamela,
Lyon James,
Yu Victor L,
Zuravleff Jeff,
Diven Warren,
Pasculle William
Publication year - 1981
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1981.131
Subject(s) - moxalactam , cephalosporin , minimum inhibitory concentration , bioassay , chemistry , creatinine , clinical pharmacology , serum concentration , pseudomonas aeruginosa , chromatography , medicine , pharmacology , antibiotics , bacteria , biology , biochemistry , genetics
Moxalactam is a new beta‐lactam antimicrobial with an extended spectrum. Serum concentrations were determined in 14 patients at steady state using bioassay and high‐pressure liquid chromatography methods. Mean peak and trough serum concentrations were 195 and 29.5 μg/ml for the 2‐gm dose and 214 and 28.8 μg/mlfor the 3‐gm dose. Peak and trough levels exceeded the minimum inhibitory concentration of the infecting bacteria in 100% and 67% of the patients. The 3‐gm dose is recommended for infections caused by Pseudomonas aeruginosa and other organisms with higher minimum inhibitory concentrations. Half‐lifes ranged from 1.7 to 5.7 hr and reflected the varying renal functions of the patients. A relationship (r = 0.878, p < 0.001) between creatinine clearance and elimination rate constant was established by bivariant linear regression analysis. Clinical Pharmacology and Therapeutics (1981) 30, 86–94; doi: 10.1038/clpt.1981.131